Overview

Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol as add-on medication to methotrexate over the long term in Japanese RA patients transferred from Study 275-08-001 (NCT00791999), and to evaluate the effects of different dosing regimens on the safety and efficacy of certolizumab pegol in American College of Rheumatology 20% (ACR20) responders who completed Study 275-08-001.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

UCB Japan Co. Ltd.

Treatments:

Certolizumab Pegol
Methotrexate